Foghorn Therapeutics
FHTX
About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Employees: 112
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
31% more capital invested
Capital invested by funds: $148M [Q1] → $193M (+$45M) [Q2]
0.82% more ownership
Funds ownership: 72.68% [Q1] → 73.49% (+0.82%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
10% less funds holding
Funds holding: 89 [Q1] → 80 (-9) [Q2]
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Financial journalist opinion
Based on 4 articles about FHTX published over the past 30 days
